AstraZeneca’s Emerging Markets Slower But Ahead Of Target
This article was originally published in PharmAsia News
Executive Summary
AstraZeneca says it came out ahead of its general guidance for emerging market product sales growth in the fourth quarter, although increases for the three months and full year remained well below those seen in 2014.